Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756410 | 0.73 | IDO1 (0.50) | IDO1KMT2AMEN1PDPK1ALDH1A1 | |
| SCHEMBL18995777 | 0.72 | PDPK1 (0.58) | IDO1TAS1R3TAS1R1TAS1R2PDPK1 | |
| SCHEMBL30056716 | 0.69 | IDO1 (0.53) | IDO1KMT2AMEN1PDPK1ALDH1A1 | |
| SCHEMBL4248158 | 0.69 | IDO1 (0.53) | IDO1KMT2AMEN1PDPK1ALDH1A1 | |
| SCHEMBL29518873 | 0.68 | IDO1 (0.68) | IDO1GID4KMT2AMEN1PDPK1 | |
| SCHEMBL3907558 | 0.68 | IDO1 (0.68) | IDO1GID4KMT2AMEN1PDPK1 | |
| SCHEMBL12727345 | 0.68 | IDO1 (0.68) | IDO1GID4KMT2AMEN1PDPK1 | |
| SCHEMBL31251494 | 0.68 | IDO1 (0.68) | IDO1GID4KMT2AMEN1PDPK1 | |
| SCHEMBL2472307 | 0.68 | IDO1 (0.68) | IDO1GID4KMT2AMEN1PDPK1 | |
| Hydrochloric Acid SCHEMBL10524447 | 0.66 | IDO1 (0.45) | IDO1KMT2AMEN1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653003-B2 | Pyrazol-4-yl carboxamide derivatives as microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653003-B2 | Pyrazol-4-yl carboxamide derivatives as microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20130281505-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130281505-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281505-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | C3AR1, CD209, CCR9 | IDO1 139/4885GID4 3777/4885KMT2A 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.